Professor Seung-gu Kang serves as a Vice president and Scientific Faculty at IMNEWRUN, where he applies generative AI and physics-based computational biophysics to design novel biologics and therapeutic modalities, such as proteins and biomolecules. He is currently an Associate Professor at Sungkyunkwan University (SKKU), affiliated with both the SKKU Advanced Institute of Nanotechnology (SAINT) and the Department of Nano Engineering. At SKKU, he leads the Generative BioDesign Lab, where his research centers on advancing generative AI-driven protein design, molecular dynamics (MD), and protein physics theories and algorithms, with applications in drug discovery and biomolecular engineering.

Prior to joining SKKU in 2024, Prof. Kang spent 13 years as a Principal Research Scientist at IBM Thomas J. Watson Research Center’s Computational Biology Center. There, he spearheaded research on molecular dynamics and generative AI theories and algorithms, utilizing supercomputers to explore the molecular mechanisms of diseases like cancer and neurodegenerative disorders. During this time, he collaborated with leading institutions such as Harvard·MGH·MIT’s Ragon Institute and Cleveland Clinic, as well as global pharmaceutical and food industry leaders, on various research initiatives.

Prof. Kang earned his Ph.D. in Theoretical and Computational Biophysics from the University of Pennsylvania in 2009, specializing in statistical mechanics-based computational protein design theories and algorithms. Notably, he was among the pioneers in developing theoretical frameworks and algorithms for protein design that incorporate noncanonical amino acids, significantly broadening the scope of protein engineering and therapeutic development.